Vance Brown - Boston Scientific Gen VP
| BSX Stock | EUR 99.00 1.00 1.00% |
Insider
Vance Brown is Gen VP of Boston Scientific
| Phone | 508 683 4000 |
| Web | https://www.bostonscientific.com |
Boston Scientific Management Efficiency
The company has return on total asset (ROA) of 0.0393 % which means that it generated a profit of $0.0393 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0408 %, meaning that it generated $0.0408 on every $100 dollars invested by stockholders. Boston Scientific's management efficiency ratios could be used to measure how well Boston Scientific manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Larry Wood | Edwards Lifesciences | 57 | |
| Christine McCauley | Edwards Lifesciences | 58 | |
| MSc MD | Medtronic PLC | N/A | |
| Ivan Fong | Medtronic PLC | 62 | |
| Hubert Allen | Abbott Laboratories | 57 | |
| JeanLuc Lemercier | Edwards Lifesciences | 66 | |
| Dirksen Lehman | Edwards Lifesciences | N/A | |
| James Young | Abbott Laboratories | N/A | |
| Melissa Brotz | Abbott Laboratories | N/A | |
| FACC MD | Becton Dickinson and | N/A | |
| Robert Ford | Abbott Laboratories | 49 | |
| Samrat Esq | Becton Dickinson and | 56 | |
| Spencer Stiles | Stryker | 46 | |
| Mark Ploof | Medtronic PLC | N/A | |
| Scott Ullem | Edwards Lifesciences | 56 | |
| Christopher DelOrefice | Becton Dickinson and | 52 | |
| Thomas Polen | Becton Dickinson and | 50 | |
| Sean Lennon | Medtronic PLC | N/A | |
| Thomas Spoerel | Becton Dickinson and | 45 | |
| Jason Beach | Stryker | N/A | |
| Michelle Quinn | Becton Dickinson and | N/A | |
Management Performance
| Return On Equity | 0.0408 | |||
| Return On Asset | 0.0393 |
Boston Scientific Leadership Team
Elected by the shareholders, the Boston Scientific's board of directors comprises two types of representatives: Boston Scientific inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boston. The board's role is to monitor Boston Scientific's management team and ensure that shareholders' interests are well served. Boston Scientific's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boston Scientific's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jodi Eddy, VP Officer | ||
| Vance Brown, Gen VP | ||
| Catherine Jennings, VP Interventions | ||
| Joseph Fitzgerald, Ex Cardiology | ||
| John Sorenson, Ex Operations | ||
| Daniel Brennan, Ex CFO | ||
| Jeffrey Mirviss, Ex Interventions | ||
| Michael Mahoney, Pres Chairman | ||
| Jonathan Monson, Global VP | ||
| Susan Lisa, VP Relations |
Boston Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boston Scientific a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0408 | |||
| Return On Asset | 0.0393 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 72.27 B | |||
| Shares Outstanding | 1.43 B | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 94.00 % | |||
| Price To Earning | 317.20 X | |||
| Price To Book | 3.80 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Boston Stock
Boston Scientific financial ratios help investors to determine whether Boston Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Boston with respect to the benefits of owning Boston Scientific security.